Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
about
The path well traveled: using mammalian retroviruses to guide research on XMRVStructure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse TranscriptaseNew insights into HIV assembly and trafficking.Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.Mechanisms of HIV-1 Control.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
P2860
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@ast
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@en
type
label
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@ast
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@en
prefLabel
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@ast
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@en
P2860
P356
P1476
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
@en
P2093
Eric O Freed
P2860
P356
10.1124/MI.9.2.5
P577
2009-04-01T00:00:00Z